Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Why Evofem Biosciences Is Soaring Today

TheMotleyFool

0 0

Why Evofem Biosciences Is Soaring TodayPhoto, wide shot, wide-angle lens, Biotech company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Sebastião Salgado: https://img.theapi.app/temp/80e18bfd-1ff8-4487-af62-1cdb7de1ceb6.png

In response to its posting positive results from a midstage clinical trial, shares of Evofem Biosciences (NASDAQ: EVFM), a clinical-stage biotech focused on women's sexual and reproductive health, had risen 13% as of 11:27 a.m. EST on Monday.

Evofem reported top-line results from its phase 2b AMPREVENCE trial, which was designed to test the efficacy and safety of its lead product candidate Amphora as a preventive treatment for urogenital chlamydia and gonorrhea in women.

Here are the key takeaways from the four-month study release:

Source Fool.com

Like: 0

EVFM

Teilen